Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. - Wikidata - awgldk - TriplyDB

Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.

Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.

http://www.wikidata.org/entity/Q45796080

about

The implication and potential applications of high-mobility group box 1 protein in breast cancer Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases The Role of HMGB1 Signaling Pathway in the Development and Progression of Hepatocellular Carcinoma: A Review Potential role of High mobility group box 1 in hepatocellular carcinoma Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment.HMGB1 in health and disease.High mobility group box-1 and its clinical value in breast cancer.Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy.Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells.Combinatorial strategies for the induction of immunogenic cell death.High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4 Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer.Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation.Genetic predisposition of six well-defined polymorphisms in HMGB1/RAGE pathway to breast cancer in a large Han Chinese population MicroRNA-218 modulates activities of glioma cells by targeting HMGB1.Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy.The multifunctional alarmin HMGB1 with roles in the pathophysiology of sepsis and cancer.The high-mobility group nucleosome-binding domain 5 is highly expressed in breast cancer and promotes the proliferation and invasion of breast cancer cells.Polymorphisms of the receptor for advanced glycation end products and glyoxalase I and long-term outcome in patients with breast cancer.Clinical and prognostic significance of high-mobility group box-1 in human gliomas.Emodin inhibits HMGB1-induced tumor angiogenesis in human osteosarcoma by regulating SIRT1.The immune response to secondary necrotic cells.Consensus guidelines for the detection of immunogenic cell death.Circulating soluble advanced glycation end product is inversely associated with the significant risk of developing cancer: evidence from a meta-analysis.MiR-216b functions as a tumor suppressor by targeting HMGB1-mediated JAK2/STAT3 signaling way in colorectal cancer.Association between intraoperative ventilator settings and plasma levels of soluble receptor for advanced glycation end-products in patients without pre-existing lung injury.Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumor-infiltrating lymphocytes (TILs) in breast cancer.High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers.Trial Watch: Chemotherapy with immunogenic cell death inducers.

P2860

Q26744069-2B9142BA-57DE-4412-9350-574A2617995F Q26768480-394984CB-E71B-44FE-A94F-215F516593B1 Q26782281-1A2755E4-7C03-4A9C-AC0C-D9B3DC150BCD Q26864508-036F0E39-2AB7-488A-9175-CD96B5CF7B0D Q34502899-670E4728-E4EB-45DE-ABDE-36D6F822E2CB Q34622835-0AF44C84-3073-4713-A966-C8A9ABF6ADEA Q35101004-43814323-E91F-4157-B041-42DE923EC779 Q35506253-15E6CDC4-E8E0-4DDA-AE58-EE5E590E8A9E Q35523700-2B276F68-474E-4D8A-96D7-F58AECA72691 Q35535140-0A6DC25F-AF6C-42A1-8AA9-579ABB3EA09A Q36621780-C1CAB635-DE24-4337-8042-F4DCC73DFC1B Q36777278-BEECE0C0-E4E1-412C-AFDC-D310ED7B01BE Q36985164-0216C09F-C328-481F-81F6-0A1C5DB89228 Q37251612-4797AEE4-1EB1-4C18-8BFC-F76E07F4C7A3 Q37293145-306F8623-B480-4A58-9A67-249CE8BCD582 Q37321088-B0F7377C-3716-4DF5-A427-0385D43462D4 Q38116712-28815188-C3C3-4AF5-87CB-B45C7FEA9A48 Q38947903-98EFA02E-468A-4C09-90E4-E5328787E138 Q40127796-52C84B8C-499C-4D21-807C-9F96D946C69A Q41983273-6BA2E76D-C7D3-4272-9A7B-2A018C3C06CE Q41995659-27A6118B-5792-4858-A1A0-51B51022ACBD Q42371859-F25B7403-AFB3-481D-ACF0-CD781A487BE1 Q42553556-271B2126-6CD1-4560-9C80-3DC6E10B533F Q43742322-D9576CB8-8CC0-467E-9816-6482C7EEC45A Q47149972-CA85ECD5-AA73-48EA-885E-A75631D3ABD0 Q50959034-92878F70-12B8-407F-907C-33668BA95F5E Q53170218-4EB26435-B856-4194-AD99-1593B4A94684 Q53192082-054078F0-45F4-4DA1-BE11-CC9FEFFD0704 Q55260834-5E6B5D7E-04E1-4E15-BABF-8201BDE94B8D

P2860

Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.

http://www.wikidata.org/entity/Q45796080

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Circulating immunogenic cell d ...... ring neoadjuvant chemotherapy.

@en

Circulating immunogenic cell d ...... ring neoadjuvant chemotherapy.

@nl

type

label

Circulating immunogenic cell d ...... ring neoadjuvant chemotherapy.

@en

Circulating immunogenic cell d ...... ring neoadjuvant chemotherapy.

@nl

prefLabel

Circulating immunogenic cell d ...... ring neoadjuvant chemotherapy.

@en

Circulating immunogenic cell d ...... ring neoadjuvant chemotherapy.

@nl

P1433

Q45796080-39075007-B37D-447D-BE98-4B148556E923

P1476

Q45796080-4656E665-9377-4871-ADA7-679A04E0F862

P2093

Q45796080-033A934B-DF39-43B9-A78C-F5C3F58672B4

Q45796080-03CBFEB7-F42E-44D4-984A-C95FA2238FC4

Q45796080-0B43C617-E196-47F4-A8B1-41F287987223

Q45796080-0BD8C581-AAF9-4E81-A7C4-C4FE1F499CB4

Q45796080-0CCB4988-8A82-4633-9AD9-E8EA11DD6362

Q45796080-4619A1A2-810D-4BB3-82EC-D4EF1F90D37F

Q45796080-782A1C4D-6FAE-46C0-A38F-5D3320C51B27

Q45796080-7C6A1B84-FC13-4D24-9673-EC247D5C0F34

Q45796080-A24E75EB-A12B-4A33-9BDD-BB0A9FA2DA1B

Q45796080-CD62A55C-340C-42F6-A46D-60DA0C6E1C17

P2860

Q45796080-01D7F40E-E3B4-486C-B6AE-7D692C6F3AD1

Q45796080-0D7A202E-3371-4DAA-8F31-9CF7CB2FA332

Q45796080-17307FAA-F4B2-4E9E-9D92-BF2E7F419B4F

Q45796080-17BF8DED-EADC-4269-A1DD-5B5FA8EFBDD2

Q45796080-1D220742-0F4E-4747-BF8A-43FD9DA1E5DA

Q45796080-2A4642D5-9C64-4D2D-8923-E3985DF787AA

Q45796080-2A58F151-3C0C-40C2-A737-BDB3F78A9638

Q45796080-2BE3EE57-3F1C-4DA1-9FB2-F4E6FE9B3070

Q45796080-38E34863-0F9D-43F0-97ED-05A40C630A8F

Q45796080-40C1931D-823E-47D1-A004-BBFC4B180F53

P2888

Q45796080-175BBDBA-FD2B-4064-B323-8402686BA6C2

P304

Q45796080-AE58D585-653E-4515-9EDA-D9EDA2B0F91D

P31

Q45796080-504A7956-D1EC-461B-B423-BBC9789DF9E8

P356

Q45796080-D3A215CA-46E5-4488-8F78-D525CAF6F26B

P433

Q45796080-62C337D5-8AD1-4D44-83DF-7E154A2ACF2C

P478

Q45796080-CE8BB641-084B-4C8E-B91F-47D2236304FE

P577

Q45796080-4DD24B18-4249-4FDA-95C4-981179E27E6F

P6179

Q45796080-8BC3803D-9232-4B6C-A0A1-EDFCD0C37761

P698

Q45796080-B4C70A2D-8762-4C08-B9A5-53A8E265E305

P921

Q45796080-C7C89FFE-5EC9-4B2D-BDD0-2FA29FFE24B2

P356

S13277-012-0513-1

P1433

P1476

Circulating immunogenic cell d ...... ring neoadjuvant chemotherapy.

@en

P2093

Axel-Mario Feller

http://www.w3.org/2001/XMLSchema#string

Barbara Siegele

http://www.w3.org/2001/XMLSchema#string

Christian J Gabka

http://www.w3.org/2001/XMLSchema#string

Christoph Salat

http://www.w3.org/2001/XMLSchema#string

Debora M I Fersching

http://www.w3.org/2001/XMLSchema#string

Dorothea Nagel

http://www.w3.org/2001/XMLSchema#string

Michael Braun

http://www.w3.org/2001/XMLSchema#string

Oliver J Stoetzer

http://www.w3.org/2001/XMLSchema#string

Oliver Steinkohl

http://www.w3.org/2001/XMLSchema#string

Stefan Holdenrieder

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2012

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

HMGB1 loves company

HMGB1 and RAGE in inflammation and cancer

High mobility group box 1 protein interacts with multiple Toll-like receptors

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

High-mobility group box 1 and cancer.

Prognostic and predictive factors in breast cancer.

P2888

s13277-012-0513-1

P304

81-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13277-012-0513-1

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1007672910

http://www.w3.org/2001/XMLSchema#string

P698

22983919

http://www.w3.org/2001/XMLSchema#string

P921